Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma
|
abstract
|
Hepatocellular carcinoma (HCC) is the most common primary liver
malignancy and the second most common cause of cancer death
worldwide. Besides sorafenib, regorafenib and lenvatinib, recent
data have shown clinical activity of the PD-1 monoclonal antibody
nivolumab. We present the case of a sorafenib-refractory patient
probably experiencing progressive disease during immune checkpoint
inhibitor combination treatment with the anti-PD-1 monoclonal
antibody nivolumab and the anti-GITR monoclonal antibody BMS-986156
within a clinical phase-1 trial followed by a prolonged tumor
response according to RECIST v.1.1 during third-line treatment with
the multi-kinase inhibitor regorafenib. Prolonged tumor response may
solely be induced by third-line regorafenib monotherapy or may
represent late treatment response to combination immunotherapy. Data
from this clinical case report support future exploration of
combination treatment of the oral multi-kinase inhibitor regorafenib
with PD-(L)1 targeted monoclonal antibodies in patients with
advanced HCC.
|
| |
|
|
citation
|
Joerger M, Gueller U, Bastian S, Driessen C, Von Moos R. Prolonged
tumor response associated with sequential immune checkpoint
inhibitor combination treatment and regorafenib in a patient with
advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol
2019; 10:373-378.
|
| |
|
|
type
|
journal paper/review (English)
|
|
date of publishing
|
4-2019
|
|
journal title
|
J Gastrointest Oncol (10/2)
|
|
ISSN print
|
2078-6891
|
|
pages
|
373-378
|
|
PubMed
|
31032109
|
|
DOI
|
10.21037/jgo.2018.11.04
|
additional links & downloads
